Pivekimab sunirine clinical trials
Also written IMGN632.
How each study uses pivekimab sunirine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pivekimab sunirine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 May 2026 · DECNUPAZ · BLA 761460 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2023 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
AbbVie (4) · Fred Hutchinson Cancer Center (1) · Children's Oncology Group (1)
Often tested with
Tested in the same studies.
Cytarabine (1) · Fludarabine phosphate (1) · Fludarabine (1) · CPX-351 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test pivekimab sunirine.
Studies
Open first, then newest update. How each study uses pivekimab sunirine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)RecruitingPhase 2/3AbbVieNCT07581002Written as Pivekimab Sunirine
- A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)RecruitingPhase 1AbbVieNCT07306832Written as Pivekimab Sunirine
- Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCNActive, not recruitingPhase 1/2AbbVieNCT03386513Written as IMGN632
- Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid NeoplasmsActive, not recruitingPhase 1Fred Hutchinson Cancer CenterNCT06034470Written as Pivekimab Sunirine
- IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaActive, not recruitingPhase 1/2AbbVieNCT04086264Written as IMGN632
- A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to TreatWithdrawnPhase 1/2Children's Oncology GroupNCT05320380Written as Anti-CD123 ADC IMGN632
Codes
What other systems call pivekimab sunirine · ClinicalTrials.gg INT017120
- UNII (FDA) L15LO3W1XXPIVEKIMAB SUNIRINEOne source FDA
- NCI Thesaurus C184834Pivekimab SunirineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L15LO3W1XX | PIVEKIMAB SUNIRINE | One source FDA |
| NCI Thesaurus | C184834 | Pivekimab Sunirine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.